Xerostomia (Dry Mouth) Therapeutics Industry Size, Manufacturing cost, Top Key Players Forecast 2025

“Over-the-counter (OTC)” segment accounts for a larger share and is expected to gain significant momentum
in the forecast period owing to wide variety & availability of branded drugs and low-cost products. Product
segmentation includes salivary substitutes, salivary stimulants, and dentrifices. Dentrifices segment accounted
for a significant market share owing to effectiveness, affordability and higher adoption.Geographic
segmentation for xerostomia (dry mouth) therapeutics industry includes North America, South America, Europe,
Asia-Pacific, Middle East and Africa.
Asia-Pacific’s xerostomia therapeutics market is anticipated to rise at a CAGR of 4.2% in the forthcoming period
due to rising awareness, high prevalence of Parkinson’s disease, cancer and HIV. North America followed by
Europe accounts for a higher revenue share owing to rising prevalence of xerostomia and other dry mouth
diseases such as rheumatoid arthritis, Sjogren’s syndrome and HIV along with rising awareness by government
and health care NGOs.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/xerostomia-dry-mouth-therapeutics-market
The key players in the xerostomia (dry mouth) therapeutics market include GlaxoSmithKline plc; Church &
Dwight Co., Inc.; Colgate-Palmolive Company; Hikma Pharmaceuticals PLC; Pendopharm; Sun Pharmaceuticals
Industries Ltd.; Lupin Pharmaceuticals, Inc.; Pfizer, Inc.; Parnell Pharmaceuticals, Inc.; Acacia Pharma; and
OraCoat.
Market Segment:
Type Outlook (Market Revenue in USD Million, 2014 - 2025)
• OTC
• Prescription
Product Outlook (Market Revenue in USD Million, 2014 - 2025)
• Salivary Stimulants
• Salivary Substitutes
• Dentifrices
Regional Outlook (Revenue, USD Million, 2014 - 2025)
• North America
• U.S.
• Canada
• Europe
• Germany
• UK